Clinical trial

Subcutaneous (SC) Darbepoetin Alfa in Subjects With Symptomatic Congestive Heart Failure (CHF) & Anemia

NCT00086086

Study summary

ClinicalTrials.gov

Subcutaneous (SC) Darbepoetin Alfa in Subjects With Symptomatic Congestive Heart Failure (CHF) & Anemia

Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE2

Loading study purpose, treatment groups and outcomes…

View the complete registry record, eligibility and contacts at ClinicalTrials.gov

Drugs and interventions used in this trial

1 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

DRUG · Mapped RxNorm record Darbepoetin Alfa Normalized identity: darbepoetin alfa View linked drug · Find medicine records · Find other trials using this name

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2003-08-01

PhasePHASE2

Conditions

Congestive Heart Failureverified · MONDO: congestive heart failure

Anemiaverified · MONDO: anemia

Interventions

Darbepoetin AlfaDRUG · verified · RxNorm: darbepoetin alfa

Sponsors & collaborators

Amgenlead sponsor

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT00086086 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.